After receiving the ethical approval in Tanzania, NeuroSolve obtained the ethical clearance in Zambia too. The ethical clearance certificate will allow to conduct medical research on Neurocysticercosis also in Zambia.

NeuroSolve is a four-year project funded by the European Commission and EDCTP3, started on May 1, 2023. The African Institutions involved are: University of Dar es Salaam (Tanzania), Sokoine University of Agriculture (Tanzania), University of Zambia (Zambia); the European Institutions are: Universiteit Ghent (Belgium) and R-Evolution Worldwide Srl – Impresa Sociale (Italy), that is also the project Coordinator. NeuroSolve is committed to fight taeniasis/Neurocysticercosis (NCC) disease in Sub-Saharan Africa.

Potrebbe essere un'immagine raffigurante testo

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

World Tuberculosis Day – March 24, 2026

Tuberculosis (TB) remains one of the leading infectious diseases worldwide. According to the WHO Global Tuberculosis Report, in 2023 an estimated 10.8 million people developed TB globally, and about 1.25

Read More

IMPROVE-HIV proposal submitted to EDCTP3 to address HIV, HBV and schistosomiasis co-infections in sub-Saharan Africa

R-Evolution WorldWide, has recently submitted the project proposal IMPROVE-HIV under the European & Developing Countries Clinical Trials Partnership (EDCTP) call HORIZON-JU-GH-EDCTP3-2026-01-HIV-03-two-stage – Global collaboration action towards better prevention, treatment and clinical management

Read More

R-Evolution Worldwide – Sierra Leone, a new local Community Based Organization

R-Evolution Worldwide – Sierra Leone is starting to operate in the Western Area Urban and Rural District of Freetown, Sierra Leone. R-Evolution Worldwide – Sierra Leone is local community-based organization, registered to

Read More